3 research outputs found
ΠΠ¦ΠΠΠΠ Π‘Π’ΠΠ’ΠΠ‘Π’ΠΠ§ΠΠ‘ΠΠΠ₯ Π₯ΠΠ ΠΠΠ’ΠΠ ΠΠ‘Π’ΠΠ ΠΠΠΠΠ ΠΠ€ΠΠ§ΠΠ‘ΠΠΠ ΠΠΠΠΠ₯Π ΠΠ Π ΠΠΠΠΠΠΠΠΠΠΠ¬ΠΠΠ Π ΠΠΠΠ‘Π’Π ΠΠ¦ΠΠ ΠΠΠΠΠ’Π ΠΠΠΠ ΠΠΠΠ‘ΠΠΠΠΠΠ
Electromyographic noise is one of the most common noises in electrocardiogram. In case of several electrocardiogram leads, electromyographic noise affects each lead to different extent. It can be taken into account when developing algorithms for multilead electrocardiogram record processing. However, in the existing literature, there is no information about the relationship of electromyographic noise in various ECG leads and their joint probability distribution. The purpose of this paper is to study statistical characteristics of electromyographic noise in ECG signal, from which the electromyographic noise is extracted. The paper proposes a method for extracting electromyographic noise from electrocardiogram signal, based on a polynomial approximation of electrocardiogram signal fragments in sliding window with overlapping fragment subsequent weight averaging. Using this method, fragments of electromyographic noise are extracted from multichannel electrocardiogram records. Based on the obtained data, a joint probability distribution function of electromyographic noise in two adjacent leads is selected, and the correlation relationships between the electromyographic noise in various ECG leads are investigated. The results show that the joint probability distribution function of electromyographic noise in two adjacent leads in the first approximation can be described using bivariate normal distribution. In addition, between the samples of electromyographic noise from two adjacent leads quite strong correlation relationships can be observed.ΠΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΏΠΎΠΌΠ΅Ρ
Π° ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ· ΡΠ°ΠΌΡΡ
ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ
ΠΏΠΎΠΌΠ΅Ρ
, ΠΏΡΠΈΡΡΡΡΡΠ²ΡΡΡΠΈΡ
Π² ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π΅. Π ΡΠ»ΡΡΠ°Π΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΠΎΡΠ²Π΅Π΄Π΅Π½ΠΈΠΉ ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π° ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΏΠΎΠΌΠ΅Ρ
Π° Π² ΡΠ°Π·Π½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΊΠ°ΠΆΠ΄ΠΎΠ΅ ΠΈΠ· ΠΎΡΠ²Π΅Π΄Π΅Π½ΠΈΠΉ. ΠΡΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΡΡΠ΅Π½ΠΎ ΠΏΡΠΈ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΠΈ Π°Π»Π³ΠΎΡΠΈΡΠΌΠΎΠ² ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΌΠ½ΠΎΠ³ΠΎΠΊΠ°Π½Π°Π»ΡΠ½ΡΡ
Π·Π°ΠΏΠΈΡΠ΅ΠΉ ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π°. ΠΠ΄Π½Π°ΠΊΠΎ Π² ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠ΅ΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΏΠΎΠ»Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ Π°Π½Π°Π»ΠΈΠ· Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Π΅ΠΉ ΠΎΡΡΡΠ΅ΡΠΎΠ² ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΎΡΠ²Π΅Π΄Π΅Π½ΠΈΡΡ
ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π°. Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β ΡΠΌΠΏΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ, Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΠΎΠΉ ΠΈΠ· Π·Π°ΡΡΠΌΠ»Π΅Π½Π½ΡΡ
ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ² ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π°. ΠΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½ ΠΌΠ΅ΡΠΎΠ΄ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ ΠΈΠ· Π·Π°ΠΏΠΈΡΠ΅ΠΉ ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π°. ΠΠ΅ΡΠΎΠ΄ ΠΎΡΠ½ΠΎΠ²Π°Π½ Π½Π° ΠΏΠΎΠ»ΠΈΠ½ΠΎΠΌΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΠΏΠΏΡΠΎΠΊΡΠΈΠΌΠ°ΡΠΈΠΈ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ² ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π° Π² ΡΠΊΠΎΠ»ΡΠ·ΡΡΠ΅ΠΌ ΠΎΠΊΠ½Π΅ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ Π²Π΅ΡΠΎΠ²ΡΠΌ ΡΡΡΠ΅Π΄Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠ΅ΡΠ΅ΠΊΡΡΠ²Π°ΡΡΠΈΡ
ΡΡ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ². Π‘ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΈΠ· ΠΌΠ½ΠΎΠ³ΠΎΠΊΠ°Π½Π°Π»ΡΠ½ΡΡ
Π·Π°ΠΏΠΈΡΠ΅ΠΉ ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π° Π±ΡΠ»ΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½Ρ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΡ ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π΅ Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ
ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ² ΠΏΠΎΠ΄ΠΎΠ±ΡΠ°Π½ΠΎ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ΅ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΡΡΡΠ΅ΡΠΎΠ² ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ Π² Π΄Π²ΡΡ
ΡΠΌΠ΅ΠΆΠ½ΡΡ
ΠΎΡΠ²Π΅Π΄Π΅Π½ΠΈΡΡ
, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΠ΅ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΠΎΡΡΡΠ΅ΡΠ°ΠΌΠΈ ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΎΡΠ²Π΅Π΄Π΅Π½ΠΈΡΡ
ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΈΠ³Π½Π°Π»Π°. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ΅ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΡΡΡΠ΅ΡΠΎΠ² ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ Π² Π΄Π²ΡΡ
ΡΠΌΠ΅ΠΆΠ½ΡΡ
ΠΎΡΠ²Π΅Π΄Π΅Π½ΠΈΡΡ
Π² ΠΏΠ΅ΡΠ²ΠΎΠΌ ΠΏΡΠΈΠ±Π»ΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΎΠΏΠΈΡΠ°Π½ΠΎ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π΄Π²ΡΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π·Π°ΠΊΠΎΠ½Π°. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΠΌΠ΅ΠΆΠ΄Ρ ΠΎΡΡΡΠ΅ΡΠ°ΠΌΠΈ ΠΌΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠ΅Ρ
ΠΈ ΠΈΠ· Π΄Π²ΡΡ
ΡΠΌΠ΅ΠΆΠ½ΡΡ
ΠΎΡΠ²Π΅Π΄Π΅Π½ΠΈΠΉ ΠΌΠΎΠ³ΡΡ Π½Π°Π±Π»ΡΠ΄Π°ΡΡΡΡ Π΄ΠΎΠ²ΠΎΠ»ΡΠ½ΠΎ ΡΠΈΠ»ΡΠ½ΡΠ΅ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΠ΅ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ
EVALUATION OF ELECTROMYOGRAPHIC NOISE STATISTICAL CHARACTERISTICS IN MULTICHANNEL ECG RECORDINGS
Electromyographic noise is one of the most common noises in electrocardiogram. In case of several electrocardiogram leads, electromyographic noise affects each lead to different extent. It can be taken into account when developing algorithms for multilead electrocardiogram record processing. However, in the existing literature, there is no information about the relationship of electromyographic noise in various ECG leads and their joint probability distribution. The purpose of this paper is to study statistical characteristics of electromyographic noise in ECG signal, from which the electromyographic noise is extracted. The paper proposes a method for extracting electromyographic noise from electrocardiogram signal, based on a polynomial approximation of electrocardiogram signal fragments in sliding window with overlapping fragment subsequent weight averaging. Using this method, fragments of electromyographic noise are extracted from multichannel electrocardiogram records. Based on the obtained data, a joint probability distribution function of electromyographic noise in two adjacent leads is selected, and the correlation relationships between the electromyographic noise in various ECG leads are investigated. The results show that the joint probability distribution function of electromyographic noise in two adjacent leads in the first approximation can be described using bivariate normal distribution. In addition, between the samples of electromyographic noise from two adjacent leads quite strong correlation relationships can be observed
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure:a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
Background: Many patients with heart failure remain symptomatic and have a poor prognosis despite existing treatments. Decreases in myocardial contractility and shortening of ventricular systole are characteristic of systolic heart failure and might be improved by a new therapeutic class, cardiac myosin activators. We report the first study of the cardiac myosin activator, omecamtiv mecarbil, in patients with systolic heart failure.
Methods: We undertook a double-blind, placebo-controlled, crossover, dose-ranging, phase 2 trial investigating the effects of omecamtiv mecarbil (formerly CK-1827452), given intravenously for 2, 24, or 72 h to patients with stable heart failure and left ventricular systolic dysfunction receiving guideline-indicated treatment. Clinical assessment (including vital signs, echocardiograms, and electrocardiographs) and testing of plasma drug concentrations took place during and after completion of each infusion. The primary aim was to assess safety and tolerability of omecamtiv mecarbil. This study is registered at ClinicalTrials.gov, NCT00624442.
Findings: 45 patients received 151 infusions of active drug or placebo. Placebo-corrected, concentration-dependent increases in left ventricular ejection time (up to an 80 ms increase from baseline) and stroke volume (up to 9Β·7 mL) were recorded, associated with a small reduction in heart rate (up to 2Β·7 beats per min; p<0Β·0001 for all three measures). Higher plasma concentrations were also associated with reductions in end-systolic (decrease of 15 mL at >500 ng/mL, p=0Β·0026) and end-diastolic volumes (16 mL, p=0Β·0096) that might have been more pronounced with increased duration of infusion. Cardiac ischaemia emerged at high plasma concentrations (two patients, plasma concentrations roughly 1750 ng/mL and 1350 ng/mL). For patients tolerant of all study drug infusions, no consistent pattern of adverse events with either dose or duration emerged.
Interpretation: Omecamtiv mecarbil improved cardiac function in patients with heart failure caused by left ventricular dysfunction and could be the first in class of a new therapeutic agent